People: Agenus Inc (AGEN.O)

AGEN.O on Consolidated Issue listed on NASDAQ Capital Market

2.66USD
23 Apr 2014
Price Change (% chg)

$-0.06 (-2.21%)
Prev Close
$2.72
Open
$2.74
Day's High
$2.78
Day's Low
$2.61
Volume
94,054
Avg. Vol
1,063,845
52-wk High
$5.40
52-wk Low
$2.27

Search Stocks

Wentworth, Kerry 

Brief Biography

Ms. Kerry A. Wentworth serves as Vice President - Clinical, Regulatory & Quality of Agenus Inc., since June 2006. Before joining Agenus Inc. in 2005, Ms. Wentworth served as senior director of regulatory affairs at Genelabs Technologies, where she was responsible for the business’ regulatory and quality functions. There she focused on the late-stage clinical development and subsequent US and European commercial application filings for the company’s lead product Prestara. Prior to Genelabs, Ms. Wentworth held various positions in regulatory affairs at Shaman Pharmaceuticals and at Genzyme Corporation. Ms. Wentworth received a BS in pre-veterinary medicine from the University of New Hampshire.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
301,540 -- 333,629 824,366

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

G Armen

2,283,670

Christine Klaskin

602,606

Robert Stein

--

Karen Valentine

766,944

Kerry Wentworth

824,366

Timothy Wright

--
As Of 30 Dec 2012
Search Stocks